EP Patent

EP1199070A2 — Use of PDE V inhibitors for improved fecundity in mammals

Assigned to Pfizer Ltd Great Britain · Expires 2002-04-24 · 24y expired

What this patent protects

The invention relates to the use of a cyclic guanosine 3', 5'-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or foetus, (b) increasing th…

USPTO Abstract

The invention relates to the use of a cyclic guanosine 3', 5'-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or foetus, (b) increasing the rate or probability of survival of an embryo and/or foetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1199070A2
Jurisdiction
EP
Classification
—
Expires
2002-04-24
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Ltd Great Britain
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.